Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
HIV and hepatitis-B lamivudine dosing differ. The single-agent and fixed-combination records must not be interchanged.
The preserved source page includes lamivudine and a zidovudine combination. Newly added adult single-agent and pediatric guidance are explicitly scoped; do not transfer single-agent dose changes to the fixed combination. NIH and the Southern African society use different renal approaches and alternatives.
Check source scope before reading a dose
NIH adult ARV table - lamivudine label and alternative doses
Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method
CrCl mL/min; HIV lamivudine, not HBV doses or combinations
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
Professional
NIH adult ARV table - lamivudine label and alternative doses
NIH ClinicalInfo adult ARV panel · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method: CrCl mL/min; HIV lamivudine, not HBV doses or combinations Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
HIV single-agent lamivudine: usual 300 mg daily or 150 mg twice daily. CrCl 15-29: 150 mg once then 100 mg daily; 5-14: 150 mg once then 50 mg daily; <5/HD: 50 mg once then 25 mg daily. NIH also lists 100-150 mg daily alternatives at these low clearances with limited evidence. Its 30-49 no-adjustment approach incorporates combination-label guidance, unlike the single-agent Epivir label. Do not transfer to lamivudine/zidovudine.
RDM30-100-lamivudine-lamivudineazt-1 · Source locator: NIH adult ARV table - lamivudine label and alternative doses; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.